Sugi Predict

Sugi Predict / Compounds / SCHEMBL995109

SCHEMBL995109

SCHEMBL995109

Cc1ccc(S(=O)(=O)OCCCN(C)C)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.54
▸ CA9 Q16790 3/20 0.54
▸ CA2 P00918 1/20 0.54
▸ ALOX15 P16050 1/20 0.53
▸ MAPT P10636 1/20 0.43
▸ MCOLN3 Q8TDD5 1/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ PSMD10 O75832 1/20 0.40
▸ CYP24A1 Q07973 1/20 0.40
▸ STAT3 P40763 1/20 0.40
▸ MAPK14 Q16539 1/20 0.40
▸ GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28996333 0.98 CA12 (0.53) CA12CA9CA2ALOX15MAPT
SCHEMBL3614979 0.90 CA12 (0.49) CA12CA9CA2ALOX15MAPT
Hydrochloric Acid SCHEMBL28936935 0.88 ALOX15 (0.50) CA12CA9CA2ALOX15MAPT
SCHEMBL483847 0.86 ALDH1A1 (0.50) CA12CA9CA2CYP2C19CYP1A2
SCHEMBL890725 0.86 ALDH1A1 (0.50) CA12CA9CA2CYP2C19CYP1A2
SCHEMBL28721741 0.85 CA12 (0.45) CA12CA9CA2ALOX15MAPT
SCHEMBL8483813 0.84 ALDH1A1 (0.48) CA12CA9CA2CYP2C19CYP1A2
SCHEMBL4815560 0.84 ALDH1A1 (0.48) CA12CA9CA2CYP2C19CYP1A2
SCHEMBL4812770 0.84 ALDH1A1 (0.48) CA12CA9CA2CYP2C19CYP1A2
SCHEMBL11050599 0.84 ALDH1A1 (0.48) CA12CA9CA2CYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814356-B1 TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) 2026-03-11 — — EP disclosed
US-12421272-B2 Artificial nucleic acid, production method therefor, and use thereof SYSMEX CORPORATION (JP) 2025-09-23 — — US disclosed
CN-113646007-B Novel artificial nucleic acid, method for producing same, and use thereof 希森美康株式会社 2024-08-23 — — CN disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) 2023-12-19 — — US disclosed
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF RIKEN GENESIS CO., LTD. (JP) 2023-08-17 — — US disclosed
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF RIKEN GENESIS CO., LTD. (JP) 2023-08-17 — — US disclosed
EP-4219517-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF Riken Genesis Co., Ltd. (JP) 2023-08-02 — — EP disclosed
CN-116322706-A Novel artificial nucleic acid, method for producing same, and use thereof 株式会社理真思 2023-06-23 — — CN disclosed
CN-110483321-B Preparation method of N-dimethylaminopropyl (meth) acrylamide 浙江鑫甬生物化工股份有限公司 2022-07-19 — — CN disclosed
US-20090156557-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-06-18 — — US disclosed
US-20090156557-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-06-18 — — US disclosed
WO-2008054956-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-05-08 — — WO disclosed
WO-2008045834-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2008-04-17 — — WO disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
US-20070117816-A1 KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-05-24 — — US disclosed
WO-2007044779-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-04-19 — — WO disclosed
WO-2006023381-A1 PYRIMIDINONE COMPOUNDS TAIGEN BIOTECHNOLOGY (TW) 2006-03-02 — — WO disclosed
US-20060036093-A1 Pyrimidinone compounds TAIGEN BIOTECHNOLOGY 2006-02-16 — — US disclosed
US-4021557-A BRONCHOSPASMOLYTICS BOEHRINGER INGELHEIM GMBH (DT) 1977-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF NSUN2, NSUN3, POLRMT CA12 2524/4885CA9 1553/4885CA2 2323/4885
US-12421272-B2 Artificial nucleic acid, production method therefor, and use thereof POLRMT, RNASEH1, METTL16 CA12 2512/4885CA9 3308/4885CA2 2062/4885
US-20070117816-A1 KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K1 CA12 4030/4885CA9 2248/4885CA2 2138/4885
US-20090156557-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 CA12 4604/4885CA9 3472/4885CA2 2993/4885
US-11845751-B2 Triazolotriazine derivatives as A2A receptor antagonists ADORA2A, ADORA1, ADORA3 CA12 3149/4885CA9 4343/4885CA2 2300/4885
US-20060036093-A1 Pyrimidinone compounds CXCR3, CCR5, CXCR5 CA12 4627/4885CA9 4135/4885CA2 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.